WO2016164703A1 - Inhibiteurs du récepteur fgfr4 - Google Patents

Inhibiteurs du récepteur fgfr4 Download PDF

Info

Publication number
WO2016164703A1
WO2016164703A1 PCT/US2016/026614 US2016026614W WO2016164703A1 WO 2016164703 A1 WO2016164703 A1 WO 2016164703A1 US 2016026614 W US2016026614 W US 2016026614W WO 2016164703 A1 WO2016164703 A1 WO 2016164703A1
Authority
WO
WIPO (PCT)
Prior art keywords
difluoro
mmol
added
title compound
stirred
Prior art date
Application number
PCT/US2016/026614
Other languages
English (en)
Inventor
Dominic Reynolds
Ming-Hong Hao
John Wang
Sundeep PRAJAPATI
Takashi Satoh
Anand SELVARAJ
Original Assignee
Eisai R & D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R & D Management Co., Ltd. filed Critical Eisai R & D Management Co., Ltd.
Publication of WO2016164703A1 publication Critical patent/WO2016164703A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Fibroblast growth factors are a family of more than 20 structurally related proteins with a variety of biological activities. Their main receptors, the fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3 and FGFR4), are a family of receptor tyrosine kinases that bind FGF and are involved in processes of cell proliferation and differentiation. Deregulation of FGFR signaling networks is implicated in a number of pathophysiological conditions, including many types of human cancers.
  • FGFR4 Fibroblast Growth Factor Receptor 4" or "FGFR4" is known to regulate proliferation and antiapoptosis and is expressed or highly expressed in many cancers. See, e.g. , Dieci et al. 2013, Cancer Discovery, 0F1-0F16. Studies have shown that expression of FGFR4 is predictive of a more aggressive phenotype of the cancer, and knockdown or reduction of FGFR4 expression serves to reduce proliferation and promote apoptosis. See, e.g., Wesche et al. 2011, Biochem J 437: 199-213.
  • FGFR4 expression or overexpression is associated with cancer
  • sarcoma such as rhabdomyosarcoma (Taylor VI et al. 2009, J Clin Invest, 119(11):3395-3407), skin cancer such as melanoma (Streit et al. 2006, British J Cancer, 94: 1879-1886), liver cancer such as cholangiocarcinoma (Sia et al. 2013, Gastroenterology 144:829-840) and hepatocellular carcinoma (French et al. 2012, PLoS ONE 7(5): e367313; Miura et al. 2012, BMC Cancer 12:56; Chiang et al.
  • pancreatic cancer such as pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma (Motoda et al. 2011, Int'l J Oncol 38: 133-143)
  • lung cancer such as non- small-cell lung cancer (Fawdar et al. 2013, PNAS 110(30): 12426- 12431), colorectal cancer (Pelaez-Garcia et al. 2013, PLoS ONE 8(5): e63695; Barderas et al.
  • a purpose of the present invention is to provide a compound of Formula I:
  • X or W is N, and the other is C, or X and W are each C;
  • Y is a divalent rou :
  • R 6 is selected from the group consisting of hydrogen and Ci- 6 alkyl
  • Ri, R 2 R 3 , and R 4 are each independently selected from the group consisting of: H, halo, Ci- 6 alkyl, and Ci- 6 alkoxy
  • R 5 is selected from the group consisting of: H, Ci- 6 alkyl, Ci- 6 alkoxy, morpholino, and halo
  • R 7 is selected from the group consisting of H and Ci alkyl
  • two of Ri, R 2 R3, and R 4 are independently selected halo (e.g. , F
  • two of Ri, R 2 R 3 , and R4 are methoxy.
  • Y is :
  • Y is :
  • Y is
  • Y is
  • Y is : In some embodiments, Y is :
  • Y is :
  • Y is :
  • R5 is selected from the group consisting of halo, methyl, and methoxy.
  • X is N and W is C.
  • X and W are each C.
  • a further purpose is to provide a compound of Formula II:
  • X or W is N, and the other is C, or X and W are each C;
  • Y is a divalent group:
  • R 6 is selected from the group consisting of hydrogen and Ci- 6 alkyl
  • Ri, R 2 R 3 , and R 4 are each independently selected from the group consisting of: H, halo, Ci- 6 alkyl, and Ci- 6 alkoxy;
  • R 5 is selected from the group consisting of: H, Ci- 6 alkyl, Ci- 6 alkoxy,
  • a further purpose is to provide a compound of Formula III:
  • a further purpose is to provide a compound of Formula IV:
  • Ri, R 2 R 3 , and R4 are each independently selected from the group consisting of: H, halo, Ci- 6 alkyl, and Ci- 6 alkoxy; one of either X or W is N, and the other is C, or X and W are each C;
  • Y is a divalent group:
  • R 6 is selected from the group consisting of hydrogen and Ci- 6 alkyland wherein R8 is selected from the group consisting of H and Ci_ 6 alkyl.
  • a further purpose is to provide a compound selected from those presented in Table 1 below, or a pharmaceutically acceptable salt thereof.
  • a further purpose is a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable carrier. In some embodiments, the composition is formulated for oral or parenteral administration.
  • a further purpose is a method of treating hepatocellular carcinoma in a subject in need thereof comprising administering to said subject a treatment effective amount of a compound or salt or composition as described herein.
  • hepatocellular carcinoma has altered FGFR4 and/or FGF19 status (e.g. , increased expression of FGFR4 and/or FGF19).
  • a further purpose is a method of treating hepatocellular carcinoma in a subject in need thereof, comprising: detecting an altered FGFR4 and/or FGF19 status (e.g. , increased expression of FGFR4 and/or FGF19) in a biological sample containing cells of said hepatocellular carcinoma, and if said hepatocellular carcinoma has said altered FGFR4 and/or FGF19 status, administering a compound or composition described herein to said subject in a treatment- effective amount.
  • an altered FGFR4 and/or FGF19 status e.g. , increased expression of FGFR4 and/or FGF19
  • a further purpose is the use of a compound or salt or a composition as described herein in a method of treatment of hepatocellular carcinoma.
  • a further purpose is the use of a compound or salt described herein in the preparation of a medicament for the treatment of hepatocellular carcinoma.
  • the compounds are selective FGFR4 inhibitors in that they have a greater binding affinity and/or inhibitory effect of FGFR4 as compared to that of FGFRl and/or FGFR2 and/or FGFR3 (e.g., by 10-fold, 100-fold, or 1000-fold greater or more).
  • compounds of the invention may optionally be substituted with one or more substituents, such as those illustrated generally herein, or as exemplified by particular classes, subclasses, and species of the invention.
  • substituted refers to the replacement of hydrogen in a given structure with a specified substituent.
  • a substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable compounds.
  • “Stable” as used herein refers to a chemically feasible compound that is not substantially altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least one week.
  • H is hydrogen
  • C is carbon
  • N is nitrogen
  • S is sulfur
  • O oxygen
  • Alkyl or “alkyl group,” as used herein, means a straight-chain (i.e., unbranched), or branched chain that is completely saturated. In some embodiments, the alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms. In certain embodiments, alkyl groups contain 1-6 carbon atoms (Ci_ 6 alkyl). In certain embodiments, alkyl groups contain 1-4 carbon atoms (Ci_ 4 alkyl). In certain
  • alkyl groups contain 1-3 carbon atoms (Ci_ 3 alkyl). In still other embodiments, alkyl groups contain 2-3 carbon atoms (C 2 - 3 alkyl), and in yet other embodiments alkyl groups contain 1-2 carbon atoms (Ci_ 2 alkyl).
  • alkenyl refers to a straight-chain (i.e., unbranched), or branched hydrocarbon chain that has one or more double bonds.
  • the alkenyl has 2, 3, 4, 5 or 6 carbon atoms.
  • alkenyl groups contain 2-8 carbon atoms (C 2 _ 8 alkenyl).
  • alkenyl groups contain 2-6 carbon atoms (C 2 _ 6 alkenyl).
  • alkenyl groups contain 3-4 carbon atoms (C 3 _ 4 alkenyl), and in yet other embodiments alkenyl groups contain 2-3 carbon atoms (C 2 _ 3 alkenyl).
  • alkenyl refers to a straight chain hydrocarbon having two double bonds, also referred to as "diene.”
  • Alkynyl or “alkynyl group” as used herein refers to a straight-chain (i.e., unbranched), branched, or cyclic hydrocarbon chain that has one or more triple bonds.
  • the alkynyl has 2, 3, 4, 5 or 6 carbon atoms.
  • alkynyl groups contain 2-8 carbon atoms (C 2 _ 8 alkynyl).
  • alkynyl groups contain 2-6 carbon atoms (C 2 _ 6 alkynyl).
  • alkynyl groups contain 3-4 carbon atoms (C 3 _ 4 alkynyl), and in yet other embodiments alkynyl groups contain 2-3 carbon atoms (C 2 _ 3 alkynyl).
  • Ar or "aryl” refer to an aromatic carbocyclic moiety having one or more closed rings. Examples include, without limitation, phenyl, naphthyl, anthracenyl, phenanthracenyl, biphenyl, and pyrenyl.
  • Halo refers to chloro (CI), fluoro (F), bromo (Br) or iodo (I).
  • Haloalkyl refers to one or more halo groups appended to the parent molecular moiety through an alkyl group. Examples include, but are not limited to, chloromethyl, fluoromethyl, trifluoromethyl, etc.
  • Heteroaryl refers to a cyclic moiety having one or more closed rings, with one or more heteroatoms (oxygen, nitrogen or sulfur) in at least one of the rings, wherein at least one of the rings is aromatic, and wherein the ring or rings may independently be fused, and/or bridged.
  • Examples include without limitation quinolinyl, isoquinolinyl, indolyl, furyl, thienyl, pyrazolyl, quinoxalinyl, pyrrolyl, indazolyl, thieno[2,3-c]pyrazolyl, benzofuryl, pyrazolo[l,5-a]pyridyl, thiophenylpyrazolyl, benzothienyl, benzothiazolyl, thiazolyl, 2-phenylthiazolyl, and isoxazolyl.
  • Alkoxy or alkylthio refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or sulfur (“alkylthio”) atom.
  • Hydrophill refers to an -OH group.
  • “-OR” refers to an R group appended to the parent molecular moiety through an oxy group, wherein R is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclo, or heteroaryl.
  • -SR refers to an R group appended to the parent molecular moiety through a sulfur atom, wherein R is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclo, or heteroaryl.
  • -SR include, but are not limited to, ethanethiyl, 3-methyl-l- butanethiyl, phenylthiyl and the like.
  • Cycloalkyl refers to a saturated cyclic hydrocarbon group containing from 3 to 8 carbons or more.
  • Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Cycloalkenyl refers to an unsaturated cyclic hydrocarbon group containing from 3 to 8 carbons or more having one or more double bonds.
  • Electrophile refers to a group having reduced electron density, typically comprising a carbon atom that is directly bonded to a more electronegative atom, such as an oxygen, nitrogen or halo.
  • electrophiles include, but are not limited to, diazomethane, trimethylsilyldiazomethane, alkyl halides, such as for example methyl iodide, benzyl bromide and the like, alkyl triflates, such as for example methyl triflate and the like, alkyl sulfonates, such as for example ethyl toluenesulfonate, butyl methanesulfonate and the like, acyl halides, such as for example acetyl chloride, benzoyl bromide and the like, acid anhydrides, such as for example acetic anhydride, succinic anhydride, maleic anhydride and the like, isocyanates, such as for example methyl
  • electrophiles are alpha-haloketones, isothiocyanates, epoxides, aziridines, sulfonyl halides, or alpha-beta-unsaturated carbonyls.
  • the electrophile is a Michael acceptor.
  • a Michael acceptor As known in the art, a
  • “Michael acceptor” is an alkene or alkyne of the form Z ; wherein Z comprises an electron withdrawing group, including, but not limited to, CHO, COR, COOR, CONRR', CONROR', CN, N0 2 , SOR, S0 2 R.
  • R may be H, alkyl, or aryl ; wherein R is alkyl, alkenyl, alkoxy or aryl.
  • azodicarboxamides and quinones are Michael acceptors. See, Santos, M.M.M. and Moreira, R., Mini-Reviews in Medicinal Chemistry, 7: 1040-1050, 2007.
  • the Michael acceptors are alpha-beta-unsaturated carbonyl compounds including, but not limited to, alpha-beta-unstaturated amides, alpha-beta-unstaturated ketones, alpha-beta- unstaturated esters, conjugated alkynyl carbonyls and alpha-beta-unsaturated nitriles.
  • Alpha-beta-unsaturated amide or “unsaturated amide” as used herein refers to an amide comprising an alkene or alkyne bonded directly to the amide carbonyl group and is represented
  • Heteroatom refers to O, S or N.
  • Heterocycle or “heterocyclyl” as used herein, means a monocyclic heterocycle, a bicyclic heterocycle, or a tricyclic heterocycle containing at least one heteroatom in the ring.
  • the monocyclic heterocycle is a 3-, 4-, 5-, 6-, 7, or 8-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S.
  • the heterocycle is a 3- or 4-membered ring containing one heteroatom selected from the group consisting of O, N and S.
  • the heterocycle is a 5-membered ring containing zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S.
  • the heterocycle is a 6-, 7-, or 8-membered ring containing zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S.
  • monocyclic heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, dihydropyranyl (including 3,4-dihydro-2H-pyran-6-yl), 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl,
  • the bicyclic heterocycles of the present invention are exemplified by a monocyclic heterocycle fused to an aryl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle.
  • bicyclic heterocycles include, but are not limited to, 3,4-dihydro-2H-pyranyl, 1,3-benzodioxolyl, 1,3-benzodithiolyl, 2,3-dihydro-l,4-benzodioxinyl, 2,3-dihydro-l-benzofuranyl, 2,3-dihydro-l-benzothienyl, 2,3- dihydro-lH-indolyl, 3,4-dihydroquinolin-2(lH)-one and 1,2,3,4- tetrahydroquinolinyl.
  • the tricyclic heterocycle is a bicyclic heterocycle fused to an aryl group, or a bicyclic heterocycle fused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to a monocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclic heterocycle.
  • tricyclic heterocycles include, but are not limited to, 2,3,4,4a,9,9a-hexahydro-lH- carbazolyl, 5a,6,7,8,9,9a-hexahydrodibenzo[b,d]furanyl, and 5a,6,7,8,9,9a-hexahydrodibenzo[b, d]thienyl.
  • the nitrogen or sulfur atoms can be optionally oxidized to various oxidation states.
  • the group S(0)o- 2 refers to -S- (sulfide), -S(O)- (sulfoxide), an -S0 2 - (sulfone) respectively.
  • nitrogens particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include those corresponding N-oxide forms.
  • a compound of the invention having, for example, a pyridyl ring; the corresponding pyridyl-N-oxide is meant to be included as another compound of the invention.
  • “Pharmaceutically acceptable salt” as used herein refer to acid addition salts or base addition salts of the compounds in the present disclosure.
  • a pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on a subject to whom it is administered and in the context in which it is administered.
  • Pharmaceutically acceptable salts include, but are not limited to, metal complexes and salts of both inorganic and carboxylic acids.
  • Pharmaceutically acceptable salts also include metal salts such as aluminum, calcium, iron, magnesium, manganese and complex salts.
  • salts include, but are not limited to, acid salts such as acetic, aspartic, alkylsulfonic, arylsulfonic, axetil, benzenesulfonic, benzoic, bicarbonic, bisulfuric, bitartaric, butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, citric, edetic, edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic, gluconic, glutamic, glycolic,
  • acid salts such as acetic, aspartic, alkylsulfonic, arylsulfonic, axetil, benzenesulfonic, benzoic, bicarbonic, bisulfuric, bitartaric, butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, citric, edetic, edisylic, esto
  • glycolylarsanilic hexamic, hexylresorcjnoic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, methanesulfonic, methylnitric, methylsulfuric, mucic, muconic, napsylic, nitric, oxalic, p- nitrophenylsulfonic, pamoic, pantothenic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalactouronic, propionic, salicylic, stearic, succinic, sulfamic, sulfanlic, sulfonic, sulfuric, tannic, tartaric, teoclic, toluenesulfonic, and the like.
  • Pharmaceutically acceptable salts may be derived from amino acids including, but not limited to, cysteine.
  • Methods for producing compounds as salts are known to those of skill in the art (see, e.g. , Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley- VCH; Verlag Helvetica Chimica Acta, Zurich, 2002; Berge et al., J. Pharm. Sci. 66: 1, 1977).
  • structures depicted herein are meant to include all enantiomeric, diastereomeric, and geometric (or conformational) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. In addition, unless otherwise stated, all rotamer forms of the compounds of the invention are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • “Isomers” refer to compounds having the same number and kind of atoms and hence the same molecular weight, but differing with respect to the arrangement or configuration of the atoms. It will be understood, however, that some isomers or racemates or others mixtures of isomers may exhibit more activity than others. "Stereoisomers” refer to isomers that differ only in the arrangement of the atoms in space. "Diastereoisomers” refer to stereoisomers that are not mirror images of each other. “Enantiomers” refers to stereoisomers that are non-superimposable mirror images of one another.
  • enantiomeric compounds taught herein may be "enantiomerically pure" isomers that comprise substantially a single enantiomer, for example, greater than or equal to 90%, 92%, 95%, 98%, or 99%, or equal to 100% of a single enantiomer.
  • enantiomeric compounds taught herein may be stereomerically pure.
  • “Stereomerically pure” as used herein means a compound or composition thereof that comprises one stereoisomer of a compound and is substantially free of other stereoisomers of that compound.
  • a stereomerically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound.
  • a typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of the other stereoisomers of the compound, more preferably greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, even more preferably greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound. See, e.g., US Patent No. 7,189,715.
  • E and Z as terms describing the geometrical isomers of substituted carbon-carbon double bonds are descriptors of the geometrical arrangement of substituents on the double bond atoms.
  • the designation of a substituted carbon-carbon double bond as “E” or “Z” is done by application of the Cahn-Ingold-Prelog priority rules, as are well known to those skilled in the art, and described in the International Union of Pure and Applied Chemistry (IUPAC) Rules for the Nomenclature of Organic Chemistry. Section E, Stereochemistry.
  • Enantiomeric excess (ee) of an enantiomer is [(the mole fraction of the major enantiomer) minus (the mole fraction of the minor enantiomer)] x 100.
  • X or W is N, and the other is C, or X and W are each C;
  • Y is a divalent group:
  • R 6 is selected from the group consisting of hydrogen and Ci- 6 alkyl
  • Ri, R 2 R 3 , and R 4 are each independently selected from the group consisting of: H, halo, Ci- 6 alkyl, and Ci- 6 alkoxy;
  • R 7 is selected from the group consisting of H and Ci alkyl
  • two of Ri, R 2 R 3 , and R 4 are independently selected halo (e.g. , F
  • two of Ri, R 2 R 3 , and R4 are methoxy.
  • Y is In some embodiments, Y is :
  • Y is
  • Y is :
  • Y is :
  • Y is :
  • Y is :
  • Y is : .
  • R5 is selected from the group consisting of halo, methyl, and methoxy.
  • X is N and W is C.
  • X and W are each C.
  • R 7 is H.
  • X or W is N, and the other is C, or X and W are each C;
  • Y is a divalent roup
  • R 6 is selected from the group consisting of hydrogen and Ci- 6 alkyl
  • Ri, R 2 R 3 , and R 4 are each independently selected from the group consisting of: H, halo, Ci- 6 alkyl, and Ci- 6 alkoxy
  • R5 is selected from the group consisting of: H, Ci- 6 alkyl, Ci- 6 alkoxy
  • Ri, R 2 R 3 , and R4 are each independently selected from the group consisting of: H, halo, Ci- 6 alkyl, and Ci- 6 alkoxy; one of either X or W is N, and the other is C, or X and W are each C;
  • Y is a divalent group:
  • R 6 is selected from the group consisting of hydrogen and Ci- 6 alkyland wherein R8 is selected from the group consisting of H and Ci_ 6 alkyl.
  • Active compounds of the present invention can be combined with a pharmaceutically acceptable carrier to provide pharmaceutical formulations thereof.
  • a pharmaceutically acceptable carrier to provide pharmaceutical formulations thereof.
  • the particular choice of carrier and formulation will depend upon the particular route of administration for which the composition is intended.
  • “Pharmaceutically acceptable carrier” refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene glycol and wool fat.
  • compositions of the present invention may be suitable for parenteral, oral, inhalation spray, topical, rectal, nasal, buccal, vaginal or implanted reservoir administration, etc.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra- synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compounds are administered intravenously, orally, subcutaneously, or via intramuscular administration.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di- glycerides.
  • Fatty acids and their glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents that are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • the active compounds may be provided in an acceptable oral dosage form, including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, may also be added.
  • useful diluents include lactose and dried cornstarch.
  • the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. In addition preservatives may also be added.
  • Suitable examples of pharmaceutically acceptable preservatives include, but are not limited to, various antibacterial and antifungal agents such as solvents, for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.).
  • solvents for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.).
  • Compounds of the present invention may be used to treat hepatocellular carcinoma.
  • Treatment refers to reversing, alleviating, delaying the onset of, inhibiting the progress of, or otherwise ameliorating a disease or disorder as described herein.
  • treatment may be administered after one or more symptoms have developed.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors).
  • Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • Patient or “subject”, as used herein, means an animal subject, preferably a mammalian subject (e.g., dog, cat, horse, cow, sheep, goat, monkey, etc.), and particularly human subjects (including both male and female subjects, and including neonatal, infant, juvenile, adolescent, adult and geriatric subjects).
  • mammalian subject e.g., dog, cat, horse, cow, sheep, goat, monkey, etc.
  • human subjects including both male and female subjects, and including neonatal, infant, juvenile, adolescent, adult and geriatric subjects.
  • treatment is provided to a subject having a cancer with altered FGFR4 and /or FGF19 (fibroblast growth factor 19) status.
  • FGF19 fibroblast growth factor 19
  • treatment may include analyzing FGFR4 and/or FGF19 status in a biological sample containing cells of said cancer, and if said cancer exhibit an FGFR4 and/or FGF19 alteration, treating a subject with a treatment effective amount of a compound or composition as described herein.
  • Altered status as used herein with reference to FGFR4 and/or FGF19 includes an increased expression thereof (e.g., increased levels of the mRNA or increased levels of the protein), increased copy number in the genome, increased activity of the encoded protein as a result of mutation, etc., as compared to a corresponding non-cancerous tissue.
  • Altered status of FGFR4 and/or FGF19 includes gene and/or encoded protein mutations that result in an increase in activity or are otherwise associated with a more aggressive form of cancer.
  • “Expression” of FGFR4 and/or FGF19 means that a gene encoding the same is transcribed, and preferably, translated. Typically, expression of a coding region will result in production of the encoded polypeptide.
  • FGFR and FGF19 proteins are known, and their altered status and/or expression may be measured using techniques standard in the art, e.g., genomic analysis of mutations or copy number aberrations such as by nucleic acid amplification, sequencing analysis, and/or hybridization-based techniques, RNA expression analysis such as northern blot or qRT-PCR, western blot or other immunoblot or immunoassay, fluorescent activated cell sorting (FACS), etc.
  • genomic analysis of mutations or copy number aberrations such as by nucleic acid amplification, sequencing analysis, and/or hybridization-based techniques
  • RNA expression analysis such as northern blot or qRT-PCR, western blot or other immunoblot or immunoassay, fluorescent activated cell sorting (FACS), etc.
  • FACS fluorescent activated cell sorting
  • Microwave heating was done using a Biotage Emrys Liberator or Initiator microwave. Column chromatography was carried out using an Isco Rf200d. Solvent removal was carried out using either a Biichi rotary evaporator or a Genevac centrifugal evaporator. Preparative LC/MS was conducted using a Waters autopurifier and 19 x 100mm XTerra 5 micron MS C18 column under acidic mobile phase conditions. NMR spectra were recorded using a Varian 400MHz spectrometer.
  • inerted e.g., a reaction vessel, flask, glass reactor, and the like
  • inert gas such as nitrogen, argon, and the like
  • DIPEA N,N-diisopropylethylamine
  • EDCI.HC1 N-(3-Dimethylaminopropyl)-N' -ethylcarbodiimide hydrochloride
  • HATU l-[Bis(dimethylamino)methylene]-lH-l,2,3-trizolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
  • TBSOTf tert-Butyldimethylsilyl trifluoromethane sulfonate
  • TESC1 Chlorotriethylsilane
  • PPTS Pyridinium p-toluenesulfonate
  • PE Petroleum ether
  • Pd 2 (dba) 3 Tris(dibenzylideneacetone) dipalladium(O) Pd(d f)2Cl2: [1,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
  • EDCI.HCl (1.18g, 6.18 mmol), HOBt (0.834g, 6.18 mmol) and triethylamine (1.7mL, 12.36 mmol) were added to a solution of 2,6-difluoro-3,5-dimethoxybenzoic acid (0.9g, 10.98 mmol) in DMF (lOmL) at 0°C under argon atmosphere and stirred for 10 min. Then 6-chloropyridin-3- amine (0.624g, 4.95 mmol) was added and the resulting reaction mixture was warmed to rt and stirred for 18h. After that, the reaction mixture was diluted with DCM and water. The aqueous layer was separated and extracted with DCM (3x50mL).
  • Triphenyl phosphine (3.33g, 12.7 mmol) and 3-(bromomethyl)-2,4-difluoro-l,5- dimethoxybenzene (3.4g, 12.7 mmol) were taken in anhydrous toluene (60mL) under argon atmosphere. The resultant clear solution was refluxed for 6h. The reaction mixture was then cooled to room temperature and filtered carefully under argon atmosphere. The obtained solid was then washed with ether and dried under high vacuum to afford desired title compound (3.2g,
  • Raney Nickel (0.06g) was added to a solution of N-(2,6-difluoro-3,5-dimethoxyphenyl)-6-((2- nitrophenyl)amino)nicotinamide (0.16g, 0.37 mmol) in MeOH (2mL) with catalytic amount of acetic acid (O.lmL) and the resultant reaction mixture was stirred for 12h at room temperature under hydrogen atmosphere (balloon). The reaction mixture was filtered through a Celite® bed. The filtrate was concentrated to afford the desired title compound (0.13g, 87%) as a solid.
  • LCMS: m/z 401.1 (M+H) + .
  • step (d) To the suspension of bromo(2,6-difluoro-3,5-dimethoxybenzyl)triphenylphosphorane (Example 513, step (d) (3.9g, 7.3 mmol) in anhydrous THF (20mL) was added 60% NaH (0.59g, 14.89 mmol) portion wise at 0 °C under argon atmosphere. The resultant reaction mixture was stirred at room temperature for 12h. A solution of 6-chloronicotinaldehyde (0.7g, 4.9 mmol) in anhydrous THF (5mL) was added drop wise for 15min. and stirring was continued for 6h at room temperature. The reaction mixture was quenched with ice water and ethyl acetate.
  • step (d) To a suspension of bromo(2,6-difluoro-3,5-dimethoxybenzyl)triphenyl- 5-phosphane (Example 513, step (d) (4.9g, 9.29 mmol) in anhydrous THF (lOmL) was added 60% NaH (0.5g, 12.67 mmol) portionwise at 0 °C under argon atmosphere. The resultant reaction mixture was stirred at room temperature for 12h. A solution of 2-chloropyrimidine-5-carbaldehyde (1.2g, 8.45 mmol) in anhydrous THF (5mL) was added dropwise for 15min. and stirring was continued for overnight at room temperature.
  • tributyl (vinyl) stannane (5.6g, 17.9 mmol) were taken in DMF (50mL) in a seal tube under argon atmosphere at room temperature. The argon gas was purged for 5-10min, then
  • TEA (0.38mL, 2.7mmol) was added to a stirred solution of Nl-(5-((3,5- dimethoxyphenyl)ethynyl)pyrimidin-2-yl)-6-methylbenzene-l,2-diamine (0.4g, l.lmmol) in anhydrous DCM (lOmL) under argon atmosphere at 0 °C.
  • the resulting mixture was stirred for 15min. and slowly added the acryloyl chloride (0.109g, 1.2mmol) at 0 °C.
  • the resulting reaction mixture was allowed to stir at 0 °C for lOmin.
  • reaction mixture was quenched with a saturated sodium bicarbonate solution (25mL) and diluted with DCM (50mL). The aqueous layer was separated and extracted with DCM (3x30mL). The organic phase was washed with brine, dried over Na 2 S0 4 , filtered and concentrated. The residue was purified by combiflash column by eluting with 0-30% ethyl acetate -hexane system to afford desired title compound (0.1 lg, 23%).
  • TEA tert-butyl (2-amino-6- fluorophenyl)(5-((2,6-difluoro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)carbamate (0.33g, 0.65mmol) in anhydrous DCM (lOmL) under argon atmosphere at 0 °C.
  • the resulting mixture was stirred for 15min. and slowly added the acryloyl chloride (0.07g, 0.78mmol) at 0 °C.
  • the resulting reaction mixture was allowed to stir at 0 °C for 30min.
  • CS 2 CO 3 (1.23g, 3.7mmol) and brettphos (0.067g, 0.12mmol) were added and the resulting reaction mixture was purged with argon gas for 5 min, followed by Pd 2 (dba) 3 (0.115g, 0.12mmol) was added. The argon gas purging was continued for additional 5min. before sealing the reaction vial. Then the reaction mixture was heated at 90 °C for 3h. After completion of the reaction by TLC, the reaction mixture was cooled to room temperature, diluted with ethyl acetate. Filtered the reaction mass through celite. The aqueous layer was separated and extracted with ethyl acetate (3x40mL).
  • N-(4-bromo-2-methyl-6-nitrophenyl)-5-iodopyrimidin-2-amine NaH (O.lg, 4.27mmol) was added to a solution of 5-iodopyrimidin-2-amine (0.5g, 2.13mmol) in DMF (5mL) and stirred the reaction mixture for lOmin at room temperature.
  • Morpholine (0.15g, 1.78mmol) was added to a degassed solution of N-(4-bromo-2-methyl-6- nitrophenyl)-5-((2,6-difluoro-3,5-dimethoxyphenyl)ethynyl)pyrimidin-2-amine (0.3g, 0.59mmol) in THF (lOmL) followed by the addition of sodium tert-butoxide (0.085g, 0.89mmol). The Argon gas was purged for 5-10min. Then di-tertbutylphosphine-2-biphenyl (0.008g, 0.029mmol) were added followed by Pd 2 (dba)3 (0.027g, 0.02mmol) was added.
  • N-Ethyl piperazine (0.45g, 3.96mmol) was added to a degassed solution of N-(4-bromo-2- methyl-6-nitrophenyl)-5-((2,6-difluoro-3,5-dimethoxyphenyl)ethynyl)pyrimidin-2-am (0.5g,
  • DIPEA (0.066g, 0.51mmol) was added to a solution of Nl-(5-((2,6-difluoro-3,5- dimethoxyphenyl)ethynyl)pyrimidin-2-yl)-4-(4-ethylpiperazin-l-yl)-6-methylbenzene-l,2- diamine (0.13g, 0.25mmol) in THF (5mL). Cooled the reaction mixture to 0 °C and added acryloyl chloride (0.023g, 0.25mmol). Stirred for lh and diluted the reaction mass with water and ethyl acetate. Ethyl acetate layer was washed with water followed by brine.
  • FGFR4 Assay of Binding to FGFR4.
  • Purified, recombinant FGFR4 was pre-incubated with 10 ⁇ compound overnight at 4 °C, or for 1 hour at room temperature. Following pre-incubation, protein samples were separated using SDS-PAGE and gels were stained with Simply Blue Safe Stain (InvitrogenTM). FGFR bands were cut out and digested using an in-gel trypsin digestion kit (Thermo Scientific, Waltham, Massachusetts). Digested samples were run on a Thermo
  • IC50 Profiling of Kinase Activity Inhibition Compounds were profiled for FGFR inhibition activity at Reaction Biology Corporation (Malvern, Pennsylvania) with their Kinase HotSpot SM assay. See, Anastassiadis et al., 2011, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29, 1039-1045.
  • FGFR1 Recombinant FGFR1 (2.5 nM), FGFR2 (1 nM), FGFR3 (5 nM), or FGFR4 (12 nM) (InvitrogenTM) was prepared as a mixture with substrate KKKS PGE Y VNIEFG (SEQ ID NO:l) (20 ⁇ , FGFRl substrate); and Poly [E,Y] 4: 1 (0.2 mg/ml, FGFR2,3,4 substrate)] in kinase reaction buffer (20 niM HEPES-HC1, pH 7.5, 10 niM MgCl 2 , 2 niM MnCl 2 , 1 niM EGTA, 0.02% Brij35, 0.1 niM Na 3 V0 4 , 0.02 mg/ml BSA, 2 mM DTT, and 1% DMSO) (reagents from Reaction Biology Corp., Malvern, Pennsylvania).
  • the IC50 activity of FGFRl is generally representative of the activity of FGFRl, FGFR2, and FGFR3. See also, Dieci et al., 2013, Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives. Cancer Discovery, F1-F16.
  • Ba/F3 is a murine, interleukin-3 dependent hematopoietic cell line, purchased from Riken Cell Bank (Ibaraki, Japan), and maintained in culture medium (RPMI-1640 (Gibco) supplemented with 10% FBS (Gibco) and 10 ng/mL recombinant mouse IL-3 (R&D Systems)).
  • RPMI-1640 Gibco
  • FBS FBS
  • 10 ng/mL recombinant mouse IL-3 R&D Systems
  • pLenti- FGFR4 or pLenti-FGFRl lentivirus were infected to the Ba/F3 parental cell lines (seeded 5E5 cells/mL, lmL/well in 12-well plate) to generate Ba/F3-FGFR4 or Ba/F3-FGFR1 by using 20ug/mL blasticidin selection marker.
  • Ba/F3-FGFR4 viability assay 4,000 cells were dispensed into each well of a 96-well plate in 90 of growth media (RPMI-1640 supplemented with 10% FBS), and incubated for 24 hours at 37°C and 5% C0 2 . 10 ⁇ ⁇ of serially diluted compound were added to appropriate wells in triplicates, and cells were incubated for 72 hours at 37°C and 5% C0 2 . Viability was measured by adding 50 ⁇ ⁇ of the CellTiter-Glo® (Promega) reagent and measuring luminescence, reported as relative light units (RLU). GI 50 values were calculated by producing nine-point dose-response curves, with normalization to media control, DMSO control and day 0 RLU measurements taken at the time of compound addition. Best-fit curves were generated with Hill equation.
  • Ba/F3-FGFR1 viability assay Assay was performed as described above for Ba/F3- FGFR4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés, des composés, des compositions pharmaceutiques et des procédés de préparation de médicaments pour le traitement du carcinome hépatocellulaire présentant un statut modifié en ce qui concerne le récepteur FGFR4 et/ou le facteur FGF19.
PCT/US2016/026614 2015-04-09 2016-04-08 Inhibiteurs du récepteur fgfr4 WO2016164703A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562145163P 2015-04-09 2015-04-09
US62/145,163 2015-04-09

Publications (1)

Publication Number Publication Date
WO2016164703A1 true WO2016164703A1 (fr) 2016-10-13

Family

ID=55759933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/026614 WO2016164703A1 (fr) 2015-04-09 2016-04-08 Inhibiteurs du récepteur fgfr4

Country Status (1)

Country Link
WO (1) WO2016164703A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018090973A1 (fr) * 2016-11-17 2018-05-24 广东众生药业股份有限公司 Inhibiteur de fgfr4, son procédé de préparation et son utilisation
WO2019085893A1 (fr) * 2017-11-01 2019-05-09 广东众生药业股份有限公司 Forme de sel et forme cristalline d'un composé utilisé en tant qu'inhibiteur de fgfr4 et procédé de préparation associé
CN109809999A (zh) * 2019-02-16 2019-05-28 安徽华胜医药科技有限公司 一种溴化合成2-溴-2-(2-氟-3-甲氧基苯基)乙酸乙酯的方法
CN109928933A (zh) * 2019-01-10 2019-06-25 安徽昊帆生物有限公司 2-氯-5-醛基嘧啶及其制备方法
WO2019242689A1 (fr) * 2018-06-22 2019-12-26 北京赛特明强医药科技有限公司 Composé de pyridine à substitution cyano et composé de pyrimidine à substitution cyano, procédé de préparation correspondant et utilisation associée
CN110997637A (zh) * 2017-09-05 2020-04-10 博奥阿迪斯生物科技公司 芳香类衍生物、其制备方法及其在医药上的应用
CN112543750A (zh) * 2018-08-03 2021-03-23 日产化学株式会社 氟化芳族仲胺化合物的制造方法
WO2021129561A1 (fr) * 2019-12-23 2021-07-01 北京赛特明强医药科技有限公司 Composé de pyridine à substitution cyano et composé de pyrimidine à substitution cyano, et leur procédé de préparation et leur utilisation
CN113896655A (zh) * 2021-12-09 2022-01-07 山东诚创蓝海医药科技有限公司 一种沃诺拉赞中间体的合成方法
CN115368219A (zh) * 2022-10-25 2022-11-22 苏州康纯医药科技有限公司 一种fgfr抑制剂关键中间体的制备方法
WO2023164538A1 (fr) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. Composés pyrazolyles utilisés en tant qu'activateurs de canal kv7
WO2023164537A1 (fr) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. Composés pyrazolyles utilisés en tant qu'activateurs de canal kv7
US11976058B2 (en) 2019-03-05 2024-05-07 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189715B2 (en) 2002-10-24 2007-03-13 Sepracor Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
WO2009046784A1 (fr) * 2007-10-09 2009-04-16 Merck Patent Gmbh Dérivés de pyridine utiles comme activateurs de glucokinase
WO2012073143A1 (fr) 2010-12-01 2012-06-07 Pfizer Inc. Inhibiteur de kat ii
WO2014149164A1 (fr) * 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Inhibiteurs mk2 et utilisations associées
WO2015057938A1 (fr) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Inhibiteurs de fgfr4 pyrimidine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189715B2 (en) 2002-10-24 2007-03-13 Sepracor Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
WO2009046784A1 (fr) * 2007-10-09 2009-04-16 Merck Patent Gmbh Dérivés de pyridine utiles comme activateurs de glucokinase
WO2012073143A1 (fr) 2010-12-01 2012-06-07 Pfizer Inc. Inhibiteur de kat ii
WO2014149164A1 (fr) * 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Inhibiteurs mk2 et utilisations associées
WO2015057938A1 (fr) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Inhibiteurs de fgfr4 pyrimidine

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
ANASTASSIADIS ET AL.: "Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity", NAT BIOTECHNOL, vol. 29, 2011, pages 1039 - 1045
BARDERAS ET AL., J PROTEOMICS, vol. 75, 2012, pages 4647 - 4655
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1
CHIANG ET AL., CANCER RES, vol. 68, no. 16, 2008, pages 6779 - 6788
DIECI ET AL., CANCER DISCOVERY, 2013, pages 0F1 - 0F16
DIECI ET AL.: "Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives", CANCER DISCOVERY, 2013, pages F1 - F16
FAWDAR ET AL., PNAS, vol. 110, no. 30, 2013, pages 12426 - 12431
FRENCH ET AL., PLOS ONE, vol. 7, no. 5, 2012, pages E367313
MIURA ET AL., BMC CANCER, vol. 12, 2012, pages 56
MOTODA ET AL., INT'L J ONCOL, vol. 38, 2011, pages 133 - 143
OLECHNO ET AL.: "Improving IC50 results with acoustic droplet ejection", JALA, vol. 11, 2006, pages 240 - 246
PELAEZ-GARCIA ET AL., PLOS ONE, vol. 8, no. 5, 2013, pages E63695
SANTOS, M.M.M.; MOREIRA, R., MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 7, 2007, pages 1040 - 1050
SAWEY ET AL., CANCER CELL, vol. 19, 2011, pages 347 - 358
SIA ET AL., GASTROENTEROLOGY, vol. 144, 2013, pages 829 - 840
STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH; VERLAG HELVETICA CHIMICA ACTA
STREIT ET AL., BRITISH J CANCER, vol. 94, 2006, pages 1879 - 1886
TAYLOR VI ET AL., J CLIN INVEST, vol. 119, no. 11, 2009, pages 3395 - 3407
WARMUTH ET AL.: "Ba/F3 cells and their use in kinase drug discovery", CURR OPIN ONCOLO, vol. 19, no. L, January 2007 (2007-01-01), pages 55 - 60
WESCHE ET AL., BIOCHEM J, vol. 437, 2011, pages 199 - 213
XU ET AL., BMC CANCER, vol. 11, 2011, pages 84
YE ET AL., CANCER, 2011, pages 5304 - 5313
ZAID ET AL., CLIN CANCER RES, vol. 19, 2013, pages 809 - 820

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109952290B (zh) * 2016-11-17 2022-05-03 广东众生药业股份有限公司 Fgfr4抑制剂及其制备方法和应用
WO2018090973A1 (fr) * 2016-11-17 2018-05-24 广东众生药业股份有限公司 Inhibiteur de fgfr4, son procédé de préparation et son utilisation
KR102249632B1 (ko) * 2016-11-17 2021-05-10 광동 쫑성 파마세티컬 컴패니, 리미티드 Fgfr4 억제제, 이의 제조 방법 및 응용
JP7063899B2 (ja) 2016-11-17 2022-05-09 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ４阻害剤、その製造方法及び使用
CN109952290A (zh) * 2016-11-17 2019-06-28 广东众生药业股份有限公司 Fgfr4 抑制剂及其制备方法和应用
KR20190077085A (ko) * 2016-11-17 2019-07-02 광동 쫑성 파마세티컬 컴패니, 리미티드 Fgfr4 억제제, 이의 제조 방법 및 응용
US11008292B2 (en) 2016-11-17 2021-05-18 Guangdong Zhongsheng Pharmaceutical Co., Ltd FGFR4 inhibitor and preparation method and use thereof
JP2019537613A (ja) * 2016-11-17 2019-12-26 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ４阻害剤、その製造方法及び使用
AU2017359819B2 (en) * 2016-11-17 2020-05-28 Guangdong Zhongsheng Pharmaceutical Co., Ltd FGFR4 inhibitor and preparation method and use thereof
EP3680236A4 (fr) * 2017-09-05 2021-04-21 Bioardis LLC Dérivé aromatique, son procédé de préparation, et ses applications médicales
CN110997637A (zh) * 2017-09-05 2020-04-10 博奥阿迪斯生物科技公司 芳香类衍生物、其制备方法及其在医药上的应用
US11279697B2 (en) 2017-09-05 2022-03-22 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
JP2020532581A (ja) * 2017-09-05 2020-11-12 バイオアーディス， エルエルシー 芳香族誘導体、その調製方法、およびその医学的適用
JP7346420B2 (ja) 2017-09-05 2023-09-19 バイオアーディス エルエルシー 芳香族誘導体、その調製方法、およびその医学的適用
CN110997637B (zh) * 2017-09-05 2022-09-27 保仕健生物科技(上海)有限公司 芳香类衍生物、其制备方法及其在医药上的应用
CN111315741A (zh) * 2017-11-01 2020-06-19 广东众生药业股份有限公司 一种作为fgfr4抑制剂化合物的盐型、晶型及其制备方法
JP7076565B2 (ja) 2017-11-01 2022-05-27 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ４阻害剤として用いられる化合物の塩形態、結晶形及びその製造方法
AU2018361264B2 (en) * 2017-11-01 2021-04-01 Guangdong Xianqiang Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
WO2019085893A1 (fr) * 2017-11-01 2019-05-09 广东众生药业股份有限公司 Forme de sel et forme cristalline d'un composé utilisé en tant qu'inhibiteur de fgfr4 et procédé de préparation associé
EP3712146A4 (fr) * 2017-11-01 2021-05-05 Guangdong Zhongsheng Pharmaceutical Co., Ltd Forme de sel et forme cristalline d'un composé utilisé en tant qu'inhibiteur de fgfr4 et procédé de préparation associé
IL274274B1 (en) * 2017-11-01 2023-07-01 Guangdong Zhongsheng Pharmaceutical Co Ltd Salt form and crystal form of compound as fgfr4 inhibitor and method of their preparation
JP2021501212A (ja) * 2017-11-01 2021-01-14 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ４阻害剤として用いられる化合物の塩形態、結晶形及びその製造方法
TWI793207B (zh) * 2017-11-01 2023-02-21 大陸商廣東衆生藥業股份有限公司 作為fgfr4抑制劑化合物的鹽型、晶型及其製備方法
US11440903B2 (en) 2017-11-01 2022-09-13 Guangdong Zhongsheng Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
KR102442369B1 (ko) 2017-11-01 2022-09-08 광동 쫑성 파마세티컬 컴패니, 리미티드 Fgfr4 억제제 화합물의 염 형태 및 결정 형태, 및 그의 제조 방법
KR20200078607A (ko) * 2017-11-01 2020-07-01 광동 쫑성 파마세티컬 컴패니, 리미티드 Fgfr4 억제제 화합물의 염 형태 및 결정 형태, 및 그의 제조 방법
CN112313207B (zh) * 2018-06-22 2023-02-14 北京赛特明强医药科技有限公司 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
WO2019242689A1 (fr) * 2018-06-22 2019-12-26 北京赛特明强医药科技有限公司 Composé de pyridine à substitution cyano et composé de pyrimidine à substitution cyano, procédé de préparation correspondant et utilisation associée
CN112313207A (zh) * 2018-06-22 2021-02-02 北京赛特明强医药科技有限公司 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN112543750A (zh) * 2018-08-03 2021-03-23 日产化学株式会社 氟化芳族仲胺化合物的制造方法
CN112543750B (zh) * 2018-08-03 2023-11-03 日产化学株式会社 氟化芳族仲胺化合物的制造方法
CN109928933B (zh) * 2019-01-10 2021-02-26 安徽昊帆生物有限公司 2-氯-5-醛基嘧啶及其制备方法
CN109928933A (zh) * 2019-01-10 2019-06-25 安徽昊帆生物有限公司 2-氯-5-醛基嘧啶及其制备方法
CN109809999A (zh) * 2019-02-16 2019-05-28 安徽华胜医药科技有限公司 一种溴化合成2-溴-2-(2-氟-3-甲氧基苯基)乙酸乙酯的方法
US11976058B2 (en) 2019-03-05 2024-05-07 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
WO2021129561A1 (fr) * 2019-12-23 2021-07-01 北京赛特明强医药科技有限公司 Composé de pyridine à substitution cyano et composé de pyrimidine à substitution cyano, et leur procédé de préparation et leur utilisation
CN113087671A (zh) * 2019-12-23 2021-07-09 北京赛特明强医药科技有限公司 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
JP7491612B2 (ja) 2019-12-23 2024-05-28 北京賽特明強医薬科技有限公司 シアノ置換ピリジンおよびシアノ置換ピリミジン系化合物、製造方法およびそれらの使用
CN113896655A (zh) * 2021-12-09 2022-01-07 山东诚创蓝海医药科技有限公司 一种沃诺拉赞中间体的合成方法
WO2023164538A1 (fr) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. Composés pyrazolyles utilisés en tant qu'activateurs de canal kv7
WO2023164537A1 (fr) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. Composés pyrazolyles utilisés en tant qu'activateurs de canal kv7
CN115368219B (zh) * 2022-10-25 2022-12-27 苏州康纯医药科技有限公司 一种fgfr抑制剂关键中间体的制备方法
CN115368219A (zh) * 2022-10-25 2022-11-22 苏州康纯医药科技有限公司 一种fgfr抑制剂关键中间体的制备方法

Similar Documents

Publication Publication Date Title
WO2016164703A1 (fr) Inhibiteurs du récepteur fgfr4
AU2018271284B2 (en) Pyrimidine FGFR4 inhibitors
RU2629194C2 (ru) Производные 1,5- и 1,7-нафтиридина, полезные при лечении заболеваний, опосредованных fgfr
EP3173412B1 (fr) Dérivé 7h-pyrrolo[2,3-d]pyrimidine 2,4-disubstituté, procédé de préparation et utilisation médicinale de ce dernier
US11498916B2 (en) Crystalline FGFR4 inhibitor compound and uses thereof
AU2018237123B2 (en) Bruton's tyrosine kinase inhibitors
WO2016029839A1 (fr) Dérivé aminé (subtitué phényle) (substitué pyrimidine), son procédé de préparation, et utilisation comme médicament
WO2007023768A1 (fr) Nouveau dérivé pyridine et dérivé pyrimidine (3)
BR112014010177B1 (pt) Composto, composição farmacêutica, e, uso de um composto
CN109310671A (zh) 布鲁顿酪氨酸激酶抑制剂
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
WO2013118817A1 (fr) Composé de quinolyl pyrrolopyrimidine ou son sel
WO2021026672A1 (fr) Inhibiteurs hétérocycliques de wdr5 utilisés en tant que composés anticancéreux
KR20230116795A (ko) 피리미딘 화합물, 조성물, 및 이들의 의약적 응용
WO2023067546A1 (fr) Nouveaux dérivés bicycliques hétéroaryles utilisés en tant qu'inhibiteurs de l'interaction protéine-protéine sos1 : kras
WO2020207476A1 (fr) Composé dérivés de pyrazolopyrazine, composition pharmaceutique et utilisation associée
KR20200090828A (ko) 피라졸로피리디논 화합물
CN112341431A (zh) 作为fgfr4抑制剂的杂环化合物
WO2016164754A1 (fr) Inhibiteurs de fgfr4
KR20210108433A (ko) 티에노피리디논 화합물
US10793566B2 (en) Bruton's tyrosine kinase inhibitors
CN116685583A (zh) 嘧啶化合物、组合物及其医药应用
WO2022212538A1 (fr) Composés pyrimidines condensés avec la diazépanone, compositions et leurs applications médicales
EA042551B1 (ru) Ингибиторы тирозинкиназы брутона

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16717229

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16717229

Country of ref document: EP

Kind code of ref document: A1